Healing of bisphosphonate-associated atypical femoral fractures in patients with osteoporosis: a comparison between treatment with and without teriparatide
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Atypical femoral fracture (AFF) often appears with bisphosphonate use. Teriparatide (TPTD) treatment may promote AFF healing, but few controlled or comparative studies have examined the effects of TPTD on healing of bisphosphonate-associated AFF. We retrospectively reviewed the medical records of 45 consecutive AFFs in 34 Japanese patients who had received oral bisphosphonates (alendronate or risedronate) for osteoporosis before AFF and had been followed for ≥12 months (range, 12-90 months). Thirty-seven complete or incomplete AFFs (82 %) were treated surgically and eight incomplete AFFs (18 %) were treated conservatively. Bisphosphonates were stopped at diagnosis. Based on TPTD use after fracture, AFFs were divided into non-TPTD (n = 24) and TPTD (n = 21) groups. Time to fracture-healing and frequency of delayed healing or non-union were compared between groups. Because fracture type (complete or incomplete) differed significantly between groups, only subanalyses for all surgically treated AFFs (complete and incomplete), surgically treated complete AFFs, and conservatively treated incomplete AFFs were performed. In subanalyses for all AFFs treated surgically, mean (± standard deviation) time to fracture healing was significantly better in the TPTD group (5.4 ± 1.5 months) than in the non-TPTD group (8.6 ± 4.7 months; P = 0.012), and the frequency of delayed healing or non-union was significantly lower in the TPTD group than in the non-TPTD group (P = 0.014). Subanalyses for surgically treated complete AFFs yielded similar results, but subanalyses for incomplete AFFs treated conservatively showed no significant differences between groups. TPTD treatment appears to significantly shorten the postoperative time to fracture healing and reduce rates of delayed healing or non-union after bisphosphonate-associated AFF.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a retrospective case–control study, Miyakoshi et al. (2015) observed a reduction in healing time and an increased union rate with the use of teriparatide [98].”
From Osteoporosis: Molecular Pathology, Diagnostics, and Therapeutics (2023) · cites this paper as [98]
Citations
Cites
(2012) · The Scientific World JOURNAL · doi:10.1100/tswj · Cited by 2,595
Shane, E., Burr, D., Abrahamsen, B., Adler, R. A., Brown, T. D., Cheung, A. M., Cosman, F., Curtis, J. R., Dell, R., Dempster, D. W., et al. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1998 · Cited by 2,147 · cited 8×
“AFF appears to be more common in patients with longterm bisphosphonate use [3, 4].”
BackgroundInfluentialZoledronic Acid and Clinical Fractures and Mortality after Hip Fracture
Lyles, K. W., Colón-Emeric, C. S., Magaziner, J. S., Adachi, J. D., Pieper, C. F., Mautalen, C., Hyldstrup, L., Recknor, C., Nordsletten, L., Moore, K. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa074941 · Cited by 2,003 · cited 1×
“Bisphosphonates have been reported to improve quality of life in patients with osteoporosis [1] and to reduce mortality in patients who have sustained hip fractures [2].”
BackgroundAspenberg, P., Genant, H. K., Johansson, T., Nino, A. J., See, K., Krohn, K., García-Hernández, P. A., Recknor, C. P., Einhorn, T. A., Dalsky, G. P., et al. (2010) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090731 · Cited by 513 · cited 1×
“A randomized clinical trial suggested a role for TPTD in accelerating healing for fractures of the distal radius in postmenopausal women [12].”
BackgroundDiagnostic criteria for primary osteoporosis: year 2000 revision
Orimo, H., Hayashi, Y., Fukunaga, M., Sone, T., Fujiwara, S., Shiraki, M., Kushida, K., Miyamoto, S., Soen, S., Nishimura, J., et al. (2001) · Journal of Bone and Mineral Metabolism · doi:10.1007/s007740170001 · Cited by 465
Bisphosphonate Therapy for Osteoporosis: Benefits, Risks, and Drug Holiday
McClung, M., Harris, S. T., Miller, P. D., Bauer, D. C., Davison, K. S., Dian, L., Hanley, D. A., Kendler, D. L., Yuen, C. K., & Lewiecki, E. M. (2013) · The American Journal of Medicine · doi:10.1016/j.amjmed.2012.06.023 · Cited by 451 · cited 2×
“However, use of bisphosphonates, particularly for long periods, is associated with an increased risk of atypical femoral fracture (AFF) [3, 4].”
BackgroundRizzoli, R., Åkesson, K., Bouxsein, M., Kanis, J. A., Napoli, N., Papapoulos, S., Reginster, J.-Y., & Cooper, C. (2011) · Osteoporosis International · doi:10.1007/s00198-010-1453-5 · Cited by 249 · cited 1×
“3 years, with an even broader range from 1 to 16 years [21].”
BackgroundThe Outcome of Surgically Treated Femur Fractures Associated With Long-Term Bisphosphonate Use
Weil, Y. A., Rivkin, G., Safran, O., Liebergall, M., & Foldes, A. J. (2011) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/ta.0b013e31821957e3 · Cited by 171 · cited 2×
“Healing of bisphosphonate-associated AFF is usually delayed [5, 6] because of suppressed bone turnover [4], and multiple operations are sometimes required despite careful attention [5, 7, 8].”
BackgroundChiang, C. Y., Zebaze, R., Ghasemzadeh, A., Iuliano-Burns, S., Hardidge, A. J., & Seeman, E. (2012) · Bone · doi:10.1016/j.bone.2012.10.006 · Cited by 153 · cited 4×
“To clarify the healing of AFFs, several case series using bone-forming agents including TPTD have recently been reported [13, 22].”
BackgroundInfluentialSahota, O., Masud, T., San, P., & Hosking, D. J. (1999) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1999.00764.x · Cited by 140 · cited 4×
“For example, because vitamin D insufficiency is known to negatively impact on BMD [25], vitamin D sufficiency may also be an important factor for healing of bisphosphonate-associated AFF by TPTD.”
BackgroundInfluential
Cited by
Items 101–115 of 115
The Role of Microdamage in Bone Mechanics and Osteoporotic Fractures
Allen, M. R. (2021) · Springer eBooks · doi:10.1007/978-981-16-5613-2_13
Bone Health and Orthopedic Surgery
Russell, L. (2014) · Springer eBooks · doi:10.1007/978-1-4614-0100-1_25
Teriparatide in fracture healing: Case series and review of literature
Jha, S. S., Jain, A. B., Dave, N., Chaturvedi, A., & Warudkar, S. (2022) · IP International Journal of Orthopaedic Rheumatology · doi:10.18231/j.ijor.2021.021
大腿骨転子下非定型骨折術後偽関節に対する積極的保存療法の一例
誠也, 神., 知哉, 松., 貞有, 泉., 勤, 河., 俊宏, 鬼., Hiratsuka, N., 均, 畑., 寿宏, 今., & 浩三, 加. (2017) · Orthopedics & Traumatology · doi:10.5035/nishiseisai.66.208
郁也, 中., 俊之, 宮., 福島達也, 憲士, 田., 森圭介, 智博, 上., 和貴, 三., & 誠, 尾. (2017) · Orthopedics & Traumatology · doi:10.5035/nishiseisai.66.688
Directive clinique no 422g : Ménopause et ostéoporose
Khan, A. A., Alrob, H. A., Ali, D. S., Dandurand, K., Wolfman, W., & Fortier, M. P. (2022) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/j.jogc.2022.03.004
非定型大腿骨不全骨折に対する予防的骨接合術後の骨癒合率について
藤村, 謙., 原, 俊., 原口明久, 健太, 加., 櫻庭康司, 嘉村, 聡., 宮原, 寿., 福士, 純., 佐々木, 大., 上田, 幸., et al. (2022) · Orthopedics & Traumatology · doi:10.5035/nishiseisai.71.853
Choi, J.-H., Hwang, K. T., Sohn, O.-J., Kook, I., & Park, K.-C. (2023) · Research Square · doi:10.21203/rs.3.rs-3153592/v1
Factors Affecting the Second Complete Atypical Femoral Fracture after the First Atypical Fracture
Tsuchie, H., Kasukawa, Y., Nozaka, K., Kinoshita, H., Sasaki, K., Aizawa, T., Mita, M., Ouchi, K., Yuasa, Y., Miura, T., et al. (2023) · Medical Principles and Practice · doi:10.1159/000535759
“Although teriparatide has been reported to enhance bone healing in patients with delayed fracture healing and AFF [9, 10], the risk of AFF in the contralateral femur and the risk of new fracture in conservatively treated incomplete AFF must be considered.”
BackgroundResultSelf-citationHow to Improve Fracture Healing in Atypical Femoral Fractures
Jeong, S.-J., Park, C.-W., & Lim, S. (2024) · The Journal of the Korean Orthopaedic Association · doi:10.4055/jkoa.2024.59.1.9
Yokozeki, Y., Miyagi, M., Kuroda, A., Murata, K., Fujimaki, H., Mimura, Y., Horiuchi, Y., Nokariya, S., Shibata, N., Tanaka, Y., et al. (2025) · Spine Surgery and Related Research · doi:10.22603/ssrr.2025-0022
“Although malnutrition 9) , muscle loss 10) , and spinal sagittal malalignment 11) have been associated with osteoporosis, their relationship to new VFs remains unclear.”
Varma, R., Wani, S., Panda, S., & Zachariah, S. (2025) · International Journal of Orthopaedics Sciences · doi:10.22271/ortho.2025.v11.i2c.3767
Nishino, T., Hyodo, K., Matsumoto, Y., Yanagisawa, Y., Shimasaki, K., Watanabe, R., Yoshizawa, T., & Mishima, H. (2026) · Diagnostics · doi:10.3390/diagnostics16020350
“Although teriparatide has been reported to promote fracture healing in atypical femoral fractures [13–15], its effect on asymptomatic incomplete lesions remains uncertain.”
川本, 浩., 森, 達., 白仁田, 厚., 河野, 勤., 松延, 知., 今村, 寿., 俊宏, 鬼., 花田, 麻., 平本, 貴., 髙﨑, 実., et al. (2026) · Orthopedics & Traumatology · doi:10.5035/nishiseisai.75.471
Chung, Y., Kim, K.-K., S., G. B., & Park, J.-S. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1909920
Metadata
- Authors
- Miyakoshi, N., Aizawa, T., Sasaki, S., Ando, S., Maekawa, S., Aonuma, H., Tsuchie, H., Sasaki, H., Kasukawa, Y., & Shimada, Y.
- Affiliations
- Akita University (JP)
- Ogachi Central Hospital (JP)
- Nakadōri General Hospital (JP)
- Akita Rosai Hospital (JP)
- Corresponding author
- Miyakoshi, Naohisa
- ORCID
- Venue
- Journal of Bone and Mineral Metabolism
- Published
- 2014-09-17
- Volume
- 33
- Issue
- 5
- Pages
- 553-559
- ISSN
- 0914-8779 (ISSN-L)
- 1435-5604
- OpenAlex
- W1996444160
- Cited by
- 114
- References
- 27
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 6 · 2023: 9 · 2022: 9 · 2021: 11 · 2020: 13 · 2019: 12 · 2018: 6 · 2017: 13 · 2016: 15 · 2015: 10 · 2014: 1
- FWCI
- 13.45
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Journal of Bone and Mineral Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone fractures and treatments
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- atypical femoral fractures, teriparatide, fracture healing, osteoporosis, alendronate, risedronate, nonunion, delayed healing, bisphosphonate discontinuation, fracture surgery
- MeSH terms
- Aged, Aged, 80 and over, Diphosphonates, Female, Femoral Fractures, Humans, Osteoporosis, Retrospective Studies, Fracture Healing, Teriparatide, Alendronate, Bone Density Conservation Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.